๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Use of aromatase inhibitors in postmenopausal women with advanced breast cancer

โœ Scribed by Roseman, Barry J.; Buzdar, Aman U.; Singletary, S. Eva

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
39 KB
Volume
66
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

โœฆ Synopsis

Surgeons have been involved in the management of metastatic breast cancer since the technique of ovarian ablation was introduced in 1896. However, as newer hormonal and chemotherapeutic regimens were developed, drug therapy gradually replaced surgery as the preferred treatment for metastatic breast cancer. Thus, management of metastatic breast cancer has largely shifted from surgeons to medical oncologists. Advances in hormonal pharmacology have placed hormonal therapy alongside surgery and radiation therapy as a standard treatment option for women with advanced breast cancer. The purpose of this article is to update surgeons on the current use of hormonal agents for treatment of advanced breast cancer in postmenopausal women, and to review the aromatase inhibitors, a new line of hormonal agents for the treatment of advanced breast cancer.

๐Ÿ“œ SIMILAR VOLUMES

Effect of the potent aromatase inhibitor
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma
โœ Luis A. M. Costa; Michael S. Kopreski; Laurence M. Demers; Vernon M. Chinchilli; ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 58 KB

## Background: Fadrozole hydrochloride (cgs 16949a) is a highly potent, nonsteroidal aromatase inhibitor that significantly lowers estrogen levels in postmenopausal women and can be effective therapy for patients with advanced hormone-dependent breast carcinoma. circulating estradiol, estrone, and

A Phase III trial comparing anastrozole
A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
โœ Aman U. Buzdar; Stephen E. Jones; Charles L. Vogel; Janet Wolter; Paul Plourde; ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 114 KB ๐Ÿ‘ 1 views

The trial was randomized, double blind for anastrozole, open label for for the Arimidex Study Group megestrol acetate, parallel group, and multicenter. Patients were randomly assigned to receive anastrozole, 1 mg (n ร… 128); anastrozole, 10 mg (n ร… 130); or

Use of calcium channel blockers and brea
Use of calcium channel blockers and breast carcinoma risk in postmenopausal women
โœ Annette L. Fitzpatrick; Janet R. Daling; Curt D. Furberg; Richard A. Kronmal; Jo ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 99 KB ๐Ÿ‘ 2 views

and Modification codes. Time-dependent Cox proportional hazards regression models Department of Epidemiology, University of were used to assess associations between incident breast carcinoma and the use of Washington, Seattle, Washington. specific antihypertensive medication including calcium chann